Nov 16, 2022 / 02:05PM GMT
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
Hi everyone, Thanks for joining us. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Yvonne Greenstreet, the CEO of Alnylam. Thanks so much for joining us today, Yvonne.
Yvonne L. Greenstreet - Alnylam Pharmaceuticals, Inc. - CEO & Director
Yes, it's a pleasure to be here. Thank you, and thank you to the audience, too, for joining us today.
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
And we're doing a fireside chat format. So maybe to start off for those who are new to the Alnylam story, if you can provide a 1-minute intro highlighting your main products and key catalysts.
Yvonne L. Greenstreet - Alnylam Pharmaceuticals, Inc. - CEO & Director
Yes, sure. Well, for those of you that are not familiar with our story, Alnylam is the leading company in RNAi therapeutics. And I think we've
Alnylam Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers